NEW YORK – Kronos Bio said on Thursday that it has dosed the first patient in a Phase I/II trial evaluating the activity of its CDK9 inhibitor, KB-0742, in MYC-amplified solid tumors.
NEW YORK – Kronos Bio said on Thursday that it has dosed the first patient in a Phase I/II trial evaluating the activity of its CDK9 inhibitor, KB-0742, in MYC-amplified solid tumors.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.